Drug Approval | December 27, 2023
Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection
The product is expected to be launched in December 2023
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
US FDA approval based on NEURO-TTRansform Phase III results
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The plant is yet to start commercial operations
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Subscribe To Our Newsletter & Stay Updated
